Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.

Journal Article (Journal Article)

A strategy for HIV-1 vaccine development is to define envelope (Env) evolution of broadly neutralizing antibodies (bnAbs) in infection and to recreate those events by vaccination. Here, we report host tolerance mechanisms that limit the development of CD4-binding site (CD4bs), HCDR3-binder bnAbs via sequential HIV-1 Env vaccination. Vaccine-induced macaque CD4bs antibodies neutralize 7% of HIV-1 strains, recognize open Env trimers, and accumulate relatively modest somatic mutations. In naive CD4bs, unmutated common ancestor knock-in mice Env+B cell clones develop anergy and partial deletion at the transitional to mature B cell stage, but become Env- upon receptor editing. In comparison with repetitive Env immunizations, sequential Env administration rescue anergic Env+ (non-edited) precursor B cells. Thus, stepwise immunization initiates CD4bs-bnAb responses, but immune tolerance mechanisms restrict their development, suggesting that sequential immunogen-based vaccine regimens will likely need to incorporate strategies to expand bnAb precursor pools.

Full Text

Duke Authors

Cited Authors

  • Williams, WB; Zhang, J; Jiang, C; Nicely, NI; Fera, D; Luo, K; Moody, MA; Liao, H-X; Alam, SM; Kepler, TB; Ramesh, A; Wiehe, K; Holland, JA; Bradley, T; Vandergrift, N; Saunders, KO; Parks, R; Foulger, A; Xia, S-M; Bonsignori, M; Montefiori, DC; Louder, M; Eaton, A; Santra, S; Scearce, R; Sutherland, L; Newman, A; Bouton-Verville, H; Bowman, C; Bomze, H; Gao, F; Marshall, DJ; Whitesides, JF; Nie, X; Kelsoe, G; Reed, SG; Fox, CB; Clary, K; Koutsoukos, M; Franco, D; Mascola, JR; Harrison, SC; Haynes, BF; Verkoczy, L

Published Date

  • November 23, 2017

Published In

Volume / Issue

  • 8 / 1

Start / End Page

  • 1732 -

PubMed ID

  • 29170366

Pubmed Central ID

  • PMC5701043

Electronic International Standard Serial Number (EISSN)

  • 2041-1723

Digital Object Identifier (DOI)

  • 10.1038/s41467-017-01336-3


  • eng

Conference Location

  • England